Table 3.
Diagnostic performance from ROC (%) in rejection vs. no rejection group.
| Biomarker | AUC | Sensitivity | Specificity | PPV | NPV | Cutoff |
|---|---|---|---|---|---|---|
| ddcfDNA (%) | 0.878 (95 CI 75.3–95.4) | 72.7 (95 CI 39–94) | 94.7 (95 CI 82.3–99.4) | 80.0 (95 CI 49.7–94.2) | 92.3 (95 CI 82.0–96.9) | 28.7% |
| ddcfDNA (cp/mL) | 0.841 (95 CI 70.8–93.0) | 81.8 (95 CI 48.2–97.7) | 81.9 (95 CI 65.7–92.3) | 56.2 (95 CI 38.4–72.6) | 93.9 (95 CI 81.4–98.2) | 2076 cp/mL |
| ALT | 0.602 (95 CI 45.1–74.0) | 100 (95 CI 71.5–100) | 35.14 (95 CI 20.2–52.5) | 31.4 (95 CI 26.6–36.7) | 100 | 258 U/L |
| AST | 0.558 (95 CI 40.7–70.1) | 90.9 (95 CI 58.7–99.8) | 32.43 (95 CI 18.0–49.8) | 28.6 (95 CI 23.0–34.9) | 92.3 (95 CI 63.6–98.8) | 224 U/L |
AUC area under the curve, dd-cfDNA donor-derived cell-free DNA, ALT alanine aminotransferase, AST aspartate aminotransferase, 95% CI 95% confidence interval, PPV positive predictive value, NPV negative predictive value.